12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Recombinant IL-7 regulatory update

Cytheris said FDA granted Orphan Drug designation for CYT107 to treat progressive multifocal leukoencephalopathy (PML). The company plans to begin a pivotal Phase IIb trial of...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >